Melfalan Amarox

Melphalan Hydrochloride, the active ingredient in Melfalan Amarox, is an alkylating agent presented as a sterile solution for intravenous or intra‑arterial use. It is employed in the treatment of various malignancies, including multiple myeloma, ovarian cancer, melanoma, neuroblastoma and other solid tumors.

GNH USA supplies Melfalan Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for import and distribution. Customers benefit from reliable logistics, temperature‑controlled shipping where required, and dedicated technical assistance.

Melphalan Hydrochloride is used as an alkylating chemotherapy agent for several malignant disease groups. - Multiple myeloma: induces DNA cross‑linking in malignant plasma cells, reducing tumor burden and prolonging survival. - Ovarian cancer: enhances cytotoxicity in ovarian tumor cells, contributing to tumor shrinkage and improved response when combined with other agents. - Melanoma: delivers potent DNA damage to metastatic melanoma cells, aiding in disease control. - Neuroblastoma: incorporated in high‑dose regimens to achieve remission in high‑risk pediatric neuroblastoma. - Other solid tumors: used within multi‑drug protocols to inhibit growth of various solid malignancies.

Melphalan Hydrochloride may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Decreased white blood cell count (neutropenia) - Anemia - Thrombocytopenia (low platelet count) - Mucositis (inflammation of the mouth lining)

Serious or Rare Side Effects: - Severe infection due to neutropenia - Acute myeloid leukemia or myelodysplastic syndrome - Renal toxicity - Pulmonary fibrosis - Cardiotoxicity - Severe allergic reactions (anaphylaxis)

When using Melphalan Hydrochloride, clinicians should observe several precautionary measures to minimize risks. - Monitor blood counts: perform regular complete blood count tests to detect cytopenias early. - Assess organ function: evaluate renal and hepatic function before each treatment cycle. - Use anti‑emetics: provide prophylactic anti‑emetic therapy to reduce nausea and vomiting. - Avoid concurrent myelosuppressive agents: limit use of other drugs that further suppress bone marrow. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan Hydrochloride can interact with other medicines, altering its efficacy or toxicity profile.

Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection due to immunosuppression. - Strong CYP450 inducers (e.g., rifampin): may reduce plasma concentrations of melphalan. - High‑dose radiation therapy: increases risk of severe tissue injury.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, heparin): heightened bleeding risk from thrombocytopenia. - Other alkylating agents: additive bone‑marrow suppression. - Nephrotoxic drugs (cisplatin, aminoglycosides): may exacerbate renal toxicity. - Granulocyte colony‑stimulating factors: may affect blood count recovery dynamics.